MAGRIN, Luigi
 Distribuzione geografica
Continente #
NA - Nord America 167
EU - Europa 100
AS - Asia 8
OC - Oceania 1
Totale 276
Nazione #
US - Stati Uniti d'America 163
IT - Italia 63
DE - Germania 11
GB - Regno Unito 11
FI - Finlandia 7
CN - Cina 4
MX - Messico 4
HK - Hong Kong 3
IE - Irlanda 3
AU - Australia 1
BE - Belgio 1
DK - Danimarca 1
ES - Italia 1
FR - Francia 1
IN - India 1
SE - Svezia 1
Totale 276
Città #
Ashburn 42
Chandler 40
Palermo 27
New York 16
Medford 9
Helsinki 7
Fairfield 6
Ludwigshafen am Rhein 6
Rome 6
Lawrence 5
Princeton 5
Beijing 4
Milan 4
Padova 4
Santa Catarina 4
Altamura 3
San Diego 3
Dublin 2
Foggia 2
Hong Kong 2
Houston 2
Los Angeles 2
Munich 2
Porto Empedocle 2
Seattle 2
Sigillo 2
Wilmington 2
Acton 1
Athlone 1
Bremen 1
Brussels 1
Canberra 1
Central 1
Chicago 1
Chiswick 1
Conegliano 1
Copenhagen 1
Edinburgh 1
Hounslow 1
Kilburn 1
La Châtre 1
London 1
Mehlingen 1
Messina 1
Milazzo 1
New Bedfont 1
Norfolk 1
Nottingham 1
Pune 1
San Paolo di Civitate 1
Southwark 1
Verona 1
Washington 1
Zaragoza 1
Totale 238
Nome #
MUTYH-associated tumor syndrome: The other face of MAP 65
POLE, POLD1, and NTHL1: the last but not the least hereditary cancer-predisposing genes 55
Prevalence and Spectrum of Germline BRCA1 and BRCA2 Variants of Uncertain Significance in Breast/Ovarian Cancer: Mysterious Signals From the Genome 47
Can the tumor-agnostic evaluation of MSI/MMR status be the common denominator for the immunotherapy treatment of patients with several solid tumors? 42
Impact of Different Selection Approaches for Identifying Lynch Syndrome-Related Colorectal Cancer Patients: Unity Is Strength 32
Exploring the Dynamic Crosstalk between the Immune System and Genetics in Gastrointestinal Stromal Tumors 22
Body mass index and baseline platelet count as predictive factors in Merkel cell carcinoma patients treated with avelumab 20
Potential agnostic role of BRCA alterations in patients with several solid tumors: One for all, all for one? 20
Prognostic and Predictive Role of Tumor-Infiltrating Lymphocytes (TILs) in Ovarian Cancer 14
Can circulating PD-1, PD-L1, BTN3A1, pan-BTN3As, BTN2A1 and BTLA levels enhance prognostic power of CA125 in patients with advanced high-grade serous ovarian cancer? 11
Low plasma PD-L1 levels, early tumor onset and absence of peritoneal carcinomatosis improve prognosis of women with advanced high-grade serous ovarian cancer 6
Totale 334
Categoria #
all - tutte 2.994
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 2.994


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2021/202254 0 0 0 0 12 0 0 4 1 1 23 13
2022/2023120 6 19 3 13 12 11 2 15 7 2 22 8
2023/2024160 8 9 11 20 8 44 14 20 0 24 2 0
Totale 334